Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2
Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) in late 2019, hundreds of millions of people have been infected worldwide. There have been unprecedented efforts in acquiring effective vaccines to confer p...
Main Authors: | Mohd Zulkifli Salleh, Mohd Nor Norazmi, Zakuan Zainy Deris |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2022-03-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/13083.pdf |
Similar Items
-
Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice
by: Airu Zhu, et al.
Published: (2021-03-01) -
Humoral and Cellular Immune Responses to Vector, Mix-and-Match, or mRNA Vaccines against SARS-CoV-2 and the Relationship between the Two Immune Responses
by: Minjeong Nam, et al.
Published: (2022-08-01) -
Pre-existing T cell immunity determines the frequency and magnitude of cellular immune response to two doses of mRNA vaccine against SARS-CoV-2
by: José L. Casado, et al.
Published: (2022-08-01) -
A specific anti‐COVID‐19 BNT162b2 vaccine‐induced early innate immune signature positively correlates with the humoral protective response in healthy and multiple sclerosis vaccine recipients
by: Martina Severa, et al.
Published: (2023-01-01) -
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects
by: Giulia Brisotto, et al.
Published: (2023-05-01)